Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

19 Jan 2005 07:00

Embargoed Release: 07:00hrs Wednesday 19 January 2005 SOPHEON PLC (`Sopheon') Atrium Medical Center Selects Sopheon's Accolade Solution to Manage Clinical Trials and Innovation Projects Software Will Support Compliance with New European-Union Clinical Trial Regulations and Help Ensure Projects Are Executed Efficiently and On Time Sopheon, the international provider of solutions that improve the return frominnovation and product development, announces that Atrium Medical Center, oneof the largest general hospitals in the Netherlands, is deploying Sopheon'sAccolade solution to support implementation of a structured process forcomprehensive management of clinical trials. Use of the software is expected tohelp Atrium enhance management of trials activity and ensure compliance withthe latest European Union (EU) clinical research regulations. Accolade willalso be used by the hospital to manage innovation projects, including majorcapital investment initiatives."Pharmaceutical companies judge our clinical-trial work by the quality of theresults and the speed and cost-effectiveness with which those results aredelivered," said Dr. Graham Ramsay of Atrium's board. "Patients depend upon ourability to effect the right kinds of innovation and make the right capitalinvestments to ensure that they receive the best available care. Sopheon'ssoftware will integrate our processes for managing clinical trials andinnovation projects, making those processes more stable, predictable andefficient."The hospital is deploying Accolade at its facilities in Heerlen, Kerkrade andBrunssum. Atrium conducts approximately 70 clinical trials per year for leadingpharmaceutical companies. It is anticipated that use of the software system,which will eventually handle as many as 240 trials at one time, will increaseclinical-trials revenue by enabling faster trial preparation and execution,higher quality results and improved service to clients. Sopheon also workedclosely with Atrium to configure Accolade to fit a new, jointly-developedprocess incorporating elements of the Six Sigma manufacturing methodology thatwill be applied to management of innovation initiatives.Accolade will replace the manual, paper-based process structure that Atriumpreviously used to manage clinical trials with a reliable, easy-to-useWeb-based framework for everything from tracking schedules and budgets toassessing and allocating resources, conducting financial analyses and examiningtrial results. The system provides hospital executives, managers, clinicaltrial coordinators, doctors and researchers with the information supportrequired for tactical, day-to-day management activity as well as for strategic,longer-term business decision-making. Atrium plans to extend access to thesystem to pharmaceutical clients interested in checking on the status of trialprojects involving their products.Sopheon's CEO Andy Michuda said:"Clinical trial management is a critical step in the cycle that movespharmaceutical products from conception and development to safe adoption in themarketplace. It's estimated that, in the United States alone, approximately80,000 clinical trials are being conducted at any one time. The scale ofopportunity associated with effecting improvements in this area is great.Accolade's capacity to reduce the expense and inefficiency of the clinicaltrial process has led to its adoption by some of the leading clinical hospitalsin the world. Atrium is one such leader, and a prime example of how forwardthinking healthcare providers are harnessing technology to benefit stakeholdersthroughout the value chain."For further information contact:Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735 Arif Karimjee, CFO Adam Reynolds Hansard Communications Tel : + 44 (0) 207 245 1100 Andrew Tan + 44 (0) 7957 203 685 Barbara Jansen Citigate First Financial Tel : + 31 (0) 205 754 010About Atrium Medical CenterWith 3600 employees and 1230 beds, Atrium Medical Center (Atrium) is one of thelargest employers in the south of the Netherlands. In 2004 Atrium celebratedits 100-year anniversary. It has a national reputation for hospital innovation,and has recently participated in experimental studies on reducing patientwait-lists, increasing care-delivery production, implementing new budgetarysystems and improving patient safety. In 2003, supported by a ¢â€š¬187 millionbudget, Atrium registered 28,000 clinical admissions, 24,000 day admissions and432,000 patient visits to its policlinics. Atrium's focus on patients,professionalism, and continuity and effectiveness of treatment ensures that thequality of care it provides remains on the highest levels.About SopheonSopheon (LSE: SPE) is an international provider of software and services. TheSopheon Accolade product development system automates gate- or phase-basedproduct development processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time-to-market. Sopheon's Monitor software operates as a "readingrobot" that automatically reviews, filters, analyzes and pushes relevantcontent to healthcare and engineering professionals to enable effectivecompliance with protocols, standards and regulations. Sopheon is listed on theAIM Market of the London Stock Exchange and on the Euronext in the Netherlands.For more information, please visit www.sopheon.com.END
Date   Source Headline
3rd Nov 202310:15 amRNSForm 8.5 (EPT/NON-RI)
3rd Nov 20238:54 amRNSForm 8.3 - Rivomore Limited - Sopheon plc
2nd Nov 20239:34 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 20233:44 pmEQSForm 8.3 - Apex Fundrock Limited : Form 8.3 Apex Fundrock Limited Re: Sopheon PLC
1st Nov 20231:55 pmRNSForm 8.3 - Sopheon plc
1st Nov 202311:23 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 202310:51 amGNWForm 8.3 - [Sopheon plc - Opening Declaration - 31 03 2023] - (CGAML)
1st Nov 202310:35 amRNSForm 8.3 - Sopheon PLC
31st Oct 20231:00 pmRNSStatement re Possible Offer
24th Aug 20237:00 amRNSInterim Results
10th Jul 20237:00 amRNSAcquisition
15th Jun 20235:06 pmRNSIssue of Equity
8th Jun 20231:35 pmRNSResult of AGM
8th Jun 20237:00 amRNSAGM Statement
13th Apr 20234:20 pmRNSIssue of Equity
31st Mar 20239:14 amRNSIssue of Equity
27th Mar 20234:23 pmRNSDirector Shareholdings
24th Mar 20237:00 amRNSDirector Share Purchases
23rd Mar 20237:00 amRNSFinal Results
22nd Feb 20234:59 pmRNSIssue of Equity
6th Feb 20237:00 amRNSDirectorate Change and Notice of Results
30th Jan 20237:00 amRNSTrading Update
20th Sep 202212:01 pmRNSSopheon launches Acclaim Line of SaaS Offerings
2nd Sep 202210:06 amRNSIssue of Equity
1st Sep 20227:00 amRNSNew Release of Award-winning Innovation Product
24th Aug 20227:00 amRNSInterim Results
16th Aug 20227:00 amRNSFive-year, $11.2m Enterprise Agreement
3rd Aug 202210:18 amRNSHolding(s) in Company
21st Jun 202212:20 pmRNSHolding(s) in Company
9th Jun 20222:30 pmRNSResult of AGM
9th Jun 20227:00 amRNSAGM Statement
6th Jun 20226:02 pmRNSIssue of Equity & TVR
23rd May 20227:00 amRNSDirector Dealing & Issue of Equity
18th May 20227:00 amRNSAcquisition
29th Apr 20225:12 pmRNSHolding(s) in Company
7th Apr 20227:00 amRNSNew Sopheon Software Release
1st Apr 202212:10 pmRNSDirector Shareholdings
24th Mar 20227:00 amRNSFinal Results
25th Jan 20227:00 amRNSTrading Update
17th Jan 20223:15 pmRNSIssue of Equity
20th Dec 20217:00 amRNSAcquisition and Trading Update
24th Sep 20211:52 pmRNSIssue of Equity
16th Sep 202110:00 amRNSHolding(s) in Company
13th Sep 20215:24 pmRNSIssue of Equity
31st Aug 20216:14 pmRNSDirector Shareholdings
25th Aug 20217:00 amRNSInterim Results
13th Jul 20217:00 amRNSNew Release Drives Business Transformation
23rd Jun 20217:00 amRNSSopheon Earns Authority to Operate for NAVSEA
15th Jun 20219:54 amRNSIssue of Equity
10th Jun 202111:43 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.